You might also be interested in:

Qingdao, the cradle of The Wandering Earth and Crazy Alien

Qingdao, China (ots) - - Picture available via http://www.presseportal.de/en/bilder - - Picture ...

ForaCare Suisse AG forms service-oriented partnership with B. Braun (PHOTO)

St. Gallen (ots) - - Partnership to introduce innovative health management technologies. - Initial product offering ...

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion (PHOTO)

Lausanne, Switzerland (ots) - Patients will be recruited in North America, Europe, South America and the Asia ...

20.05.2010 – 12:53

Roche Pharmaceuticals

/K I L L K I L L K I L L -- Roche/

Journalists and other readers should disregard the news release "Phase III Study Showed First-Line Maintenance use of MabThera Doubles Likelihood of People With Follicular Lymphoma Living Without Their Disease Worsening" OTC:RHHVF, issued earlier today. The information contained within this press release should have been embargoed until 23:00BST, May 20th.

Contact:

CONTACT: Roche Group Media Relations, Phone: +41-61-688-8888,
e-mail:basel.mediaoffice@roche.com, Alexander Klauser, Martina Rupp,
ClaudiaSchmitt, Nina Schwab-Hautzinger

Original content of: Roche Pharmaceuticals, transmitted by news aktuell

All Releases
Subscribe to Roche Pharmaceuticals
  • Printable version
  • PDF version

Topics in this relase